Close Menu

SAN FRANCISCO - On the fourth day of the 38th annual JP Morgan Healthcare Conference, Five Prime Therapeutics provided an update on the development of bemarituzumab and FPA150, and Gritstone Oncology discussed plans for its personalized immunotherapies. Below are brief reports on the presentations covered by our team at the conference and in our offices in New York.


Five Prime

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.